Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ocular Therapeut (NQ: OCUL )

5.125 +0.385 (+8.12%)
Streaming Delayed Price Updated: 11:33 AM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ocular Therapeut

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
It's time to start the day off right with a look at the biggest pre-market stock movers to watch for Thursday morning! 
Via InvestorPlace
Adobe Issues Weak Forecast, Joins Mueller Water Products, AerSale And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow Jones futures gaining around 70 points on Thursday. Shares of Adobe Inc. (NASDAQ: ADBE) shares moved lower in pre-market trading following the... 
Via Benzinga
Topics Stocks
Exposures US Equities
What Happened To Ocular Therapeutix Stock After-Hours?
Ocular Therapeutix, Inc. (NASDAQ: OCUL) shares are trading lower in Wednesday's after-hours session. 
Via Benzinga
Recap: Ocular Therapeutix Q3 Earnings
Via Benzinga
A Preview Of Ocular Therapeutix's Earnings
Via Benzinga
5 Analysts Have This to Say About Ocular Therapeutix
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Top 5 Health Care Stocks That Are Ticking Portfolio Bombs
As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20... 
Via Benzinga
Expert Ratings for Ocular Therapeutix
Via Benzinga
What 5 Analyst Ratings Have To Say About Ocular Therapeutix
Via Benzinga
Looking Into Ocular Therapeutix's Return On Capital Employed
Via Benzinga
The Latest Analyst Ratings for Ocular Therapeutix
Via Benzinga
Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement
Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make... 
Via Talk Markets
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
R&D Activities for Treating Dry Eye Syndrome Resulting in Promising Pipeline of Treatments
EQNX::TICKER_START (NASDAQ:OKYO),(NYSE:NVS),(NASDAQ:ALDX),(NASDAQ:OCUL),(NASDAQ:EYPT) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Earnings Outlook For Ocular Therapeutix
Via Benzinga
Why Shares of Ocular Therapeutix Jumped This Week
A promising report of a therapy in a phase 1 trial gave the stock a lift. 
Via The Motley Fool
Why MIND Technology Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers WeTrade Group, Inc. (NASDAQ: WETG) shares climbed 140.3% to $20.28. WeTrade launched large-scale language processing models to increase product applications in the field of artificial... 
Via Benzinga
OKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
Drug development can be notoriously slow, and it can take some companies 10 years or more to pass through all the trials and tests required by the Food and Drug Administration (FDA). 
Via Benzinga
OKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In March 2023, Anticipates Releasing Topline Results By Q4
Drug development isn’t known for being fast-paced, and developing any new drug is generally a long process. However, OKYO Pharma Ltd. (NASDAQ: OKYO) is moving quickly to develop its eye treatment drug,... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2023
Via Benzinga
Dick's Sporting Goods, WW International, Sea Limited And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 150 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Tesla, Solaredge, Palantir, Cleveland-Cliffs, Ocular Therapeutix: Why These 5 Stocks Are Drawing Heavy Attention Today
Major Wall Street indices closed over 1% higher on Monday ahead of the release of the consumer price index report on Tuesday. The Nasdaq Composite closed 1.48% higher while the S&P 500 ended the... 
Via Benzinga
Dow Gains Over 300 Points; S&P 500 Up 1%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining over 300 points on Monday. The Dow traded up 1.01% to 34,211.29 while the NASDAQ rose 1.52% to 11,896.33. The S&P 500... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Rises 1.5%; G1 Therapeutics Shares Plummet
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.5% on Monday. The Dow traded up 0.96% to 34,193.83 while the NASDAQ rose 1.52% to 11,896.75. The S&P 500... 
Via Benzinga
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.